Skip to main content

Table 4 HR and 95% CI for the associations between risk factors and 5-year recurrence by tumor molecular subtype

From: Breast cancer risk factors, survival and recurrence, and tumor molecular subtype: analysis of 3012 women from an indigenous Asian population

Risk factora

Recurrence after 5 years

P-hetd

A-like

B-like

HER2-enriched

Triple-negative

N/events

HR (95% CI)

N/events

HR (95% CI)

N/events

HR (95% CI)

N/events

HR (95% CI)

Ethnicity

 Chinese

567/34

1.00 (reference)

435/49

1.00 (reference)

180/30

1.00 (reference)

275/38

1.00 (reference)

0.96

 Malay

204/8

1.01 (0.39, 2.60)

263/30

0.81 (0.45, 1.45)

104/17

0.69 (0.31, 1.51)

155/24

1.11 (0.61, 2.02)

 

 Native

245/16

1.17 (0.49, 2.79)

291/22

0.84 (0.46, 1.55)

103/10

0.47 (0.18, 1.23)

190/22

0.67 (0.34, 1.34)

 

 P value

 

0.75

 

0.55

 

0.11

 

0.32

 

Menarche

  ≤ 12 yrs

344/13

1.00 (reference)

326/38

1.00 (reference)

118/14

1.00 (reference)

190/34

1.00 (reference)

0.07

 13 yrs

318/17

1.55 (0.57, 4.23)

340/31

1.03 (0.58, 1.82)

148/21

1.52 (0.69, 3.33)

201/24

0.72 (0.38, 1.37)

 

 14 yrs

163/14

2.51 (0.86, 7.33)

167/21

0.81 (0.40, 1.64)

60/9

0.56 (0.16, 1.92)

111/13

0.65 (0.30, 1.43)

 

  ≥ 15 yrs

184/13

3.26 (1.08, 9.92)

148/11

0.77 (0.35, 1.68)

57/12

1.11 (0.38, 3.28)

113/12

0.61 (0.27, 1.36)

 

 P value

 

0.02

 

0.41

 

0.81

 

0.18

 

Parity and BFc

 Nulliparous

242/19

1.00 (reference)

224/16

1.00 (reference)

77/12

1.00 (reference)

128/19

1.00 (reference)

0.56

 Parous and No BF

133/7

0.55 (0.20, 1.50)

103/14

1.86 (0.76, 4.56)

31/7

1.35 (0.39, 4.64)

64/17

1.57 (0.67, 3.66)

 

 Parous and BF

641/32

0.27 (0.12, 0.58)

662/71

1.63 (0.81, 3.28)

279/38

0.58 (0.25, 1.34)

428/48

0.77 (0.39, 1.52)

 

 P value

 

0.001

 

0.23

 

0.15

 

0.28

 

Age at FFPd

  < 25

400/13

1.00 (reference)

445/44

1.00 (reference)

183/30

1.00 (reference)

294/41

1.00 (reference)

0.52

  ≥ 25

374/26

1.69 (0.66, 4.34)

320/41

1.32 (0.78, 2.22)

127/15

0.50 (0.21, 1.16)

197/23

0.75 (0.41, 1.39)

 

 P value

 

0.27

 

0.28

 

0.10

 

0.36

 

Family history

 No

840/42

1.00 (reference)

854/85

1.00 (reference)

338/49

1.00 (reference)

516/66

1.00 (reference)

0.94

 Yes

160/13

0.77 (0.29, 2.03)

119/14

1.17 (0.60, 2.28)

46/7

1.24 (0.45, 3.35)

92/12

0.85 (0.43, 1.70)

 

 P value

 

0.60

 

0.64

 

0.67

   

BMI, kg/m2

 18.5–24.9

160/6

1.00 (referent)

172/14

1.00 (referent)

68/11

1.00 (referent)

114/16

1.00 (referent)

0.98

  < 18.5

373/30

3.97 (0.91, 17.34)

336/29

1.37 (0.62, 3.03)

163/21

0.50 (0.20, 1.27)

240/30

1.01 (0.51, 2.01)

 

 P value

 

0.06

 

0.43

 

0.15

 

0.97

 

 25–30

317/16

3.40 (0.75, 15.42)

301/37

2.02 (0.95, 4.29)

104/15

0.70 (0.27, 1.81)

177/24

0.83 (0.39, 1.73)

 

 P value

 

0.11

 

0.06

 

0.46

 

0.62

 

  > 30

136/5

1.65 (0.27, 10.15)

148/15

1.28 (0.53, 3.12)

38/7

1.41 (0.46, 4.27)

66/13

0.89 (0.35, 2.25)

 

 P value

 

0.59

 

0.58

 

0.55

 

0.81

 
  1. In bold are variables which met our criteria (P-value < 0.1) for inclusion in multivariate models
  2. aEach risk factor was adjusted for age, ethnicity, BMI, tumor stage, histologic grade, surgery, systemic therapy (endocrine (tamoxifen or AI versus none), chemotherapy (any regimen versus none)) and radiotherapy (received versus none)
  3. bBF breastfeeding
  4. cFFP first full-term pregnancy. Due to sample size considerations age at FFP was dichotomized
  5. dP value for heterogeneity (P-het) of HR estimates according to molecular subtypes